Page last updated: 2024-08-24

ibandronic acid and docetaxel anhydrous

ibandronic acid has been researched along with docetaxel anhydrous in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S1
Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U1
Engelmann, U; Epplen, R; Heidenreich, A; Ohlmann, CH; Stöckle, M1

Reviews

1 review(s) available for ibandronic acid and docetaxel anhydrous

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for ibandronic acid and docetaxel anhydrous

ArticleYear
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
    International journal of cancer, 1999, Oct-08, Volume: 83, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured

1999
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
    Oncology reports, 2004, Volume: 12, Issue:5

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid

2004
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
    Clinical breast cancer, 2005, Volume: 6, Issue:5

    Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab

2005
Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Diphosphonates; Docetaxel; Drug Synergism; Farnesol; Humans; Ibandronic Acid; Male; Mevalonic Acid; Prenylation; Prostatic Neoplasms; Signal Transduction; Taxoids

2011